JP2005507647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507647A5 JP2005507647A5 JP2003514001A JP2003514001A JP2005507647A5 JP 2005507647 A5 JP2005507647 A5 JP 2005507647A5 JP 2003514001 A JP2003514001 A JP 2003514001A JP 2003514001 A JP2003514001 A JP 2003514001A JP 2005507647 A5 JP2005507647 A5 JP 2005507647A5
- Authority
- JP
- Japan
- Prior art keywords
- ser
- peptide
- leu
- pharmaceutical composition
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 150000001413 amino acids Chemical group 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000002775 capsule Substances 0.000 claims 8
- 210000002784 stomach Anatomy 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 7
- 210000000481 breast Anatomy 0.000 claims 5
- 210000002808 connective tissue Anatomy 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 210000005069 ears Anatomy 0.000 claims 5
- 210000001508 eye Anatomy 0.000 claims 5
- 210000003563 lymphoid tissue Anatomy 0.000 claims 5
- 210000000214 mouth Anatomy 0.000 claims 5
- 210000003205 muscle Anatomy 0.000 claims 5
- 210000001331 nose Anatomy 0.000 claims 5
- 210000002741 palatine tonsil Anatomy 0.000 claims 5
- 210000003800 pharynx Anatomy 0.000 claims 5
- 210000002307 prostate Anatomy 0.000 claims 5
- 210000003491 skin Anatomy 0.000 claims 5
- 206010062767 Hypophysitis Diseases 0.000 claims 4
- 210000004100 adrenal gland Anatomy 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 210000001072 colon Anatomy 0.000 claims 4
- 210000003238 esophagus Anatomy 0.000 claims 4
- 210000000232 gallbladder Anatomy 0.000 claims 4
- 210000004392 genitalia Anatomy 0.000 claims 4
- 210000002216 heart Anatomy 0.000 claims 4
- 210000000936 intestine Anatomy 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 210000001165 lymph node Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000001672 ovary Anatomy 0.000 claims 4
- 210000000496 pancreas Anatomy 0.000 claims 4
- 210000002990 parathyroid gland Anatomy 0.000 claims 4
- 210000003635 pituitary gland Anatomy 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 210000000664 rectum Anatomy 0.000 claims 4
- 210000003079 salivary gland Anatomy 0.000 claims 4
- 210000000278 spinal cord Anatomy 0.000 claims 4
- 210000000952 spleen Anatomy 0.000 claims 4
- 210000001550 testis Anatomy 0.000 claims 4
- 210000001685 thyroid gland Anatomy 0.000 claims 4
- 210000003932 urinary bladder Anatomy 0.000 claims 4
- 210000004291 uterus Anatomy 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 231100000572 poisoning Toxicity 0.000 claims 2
- 230000000607 poisoning effect Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000027219 Deficiency disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000028782 Hereditary disease Diseases 0.000 claims 1
- 102000016997 Lithostathine Human genes 0.000 claims 1
- 108010014691 Lithostathine Proteins 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 238000000315 cryotherapy Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000005868 electrolysis reaction Methods 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 210000004209 hair Anatomy 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000002647 laser therapy Methods 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30616101P | 2001-07-19 | 2001-07-19 | |
| US30615001P | 2001-07-19 | 2001-07-19 | |
| US33147701P | 2001-11-16 | 2001-11-16 | |
| PCT/CA2002/001105 WO2003008443A2 (en) | 2001-07-19 | 2002-07-19 | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011035954A Division JP2011152133A (ja) | 2001-07-19 | 2011-02-22 | 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507647A JP2005507647A (ja) | 2005-03-24 |
| JP2005507647A5 true JP2005507647A5 (enExample) | 2006-01-05 |
Family
ID=27405149
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003514002A Expired - Lifetime JP4587667B2 (ja) | 2001-07-19 | 2002-07-19 | 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド |
| JP2003514001A Pending JP2005507647A (ja) | 2001-07-19 | 2002-07-19 | 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド |
| JP2011035954A Pending JP2011152133A (ja) | 2001-07-19 | 2011-02-22 | 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド |
| JP2013078281A Expired - Lifetime JP5622885B2 (ja) | 2001-07-19 | 2013-04-04 | 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003514002A Expired - Lifetime JP4587667B2 (ja) | 2001-07-19 | 2002-07-19 | 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011035954A Pending JP2011152133A (ja) | 2001-07-19 | 2011-02-22 | 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド |
| JP2013078281A Expired - Lifetime JP5622885B2 (ja) | 2001-07-19 | 2013-04-04 | 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7241738B2 (enExample) |
| EP (2) | EP1417227B1 (enExample) |
| JP (4) | JP4587667B2 (enExample) |
| KR (2) | KR100966232B1 (enExample) |
| CN (1) | CN100475843C (enExample) |
| AT (1) | ATE353914T1 (enExample) |
| AU (2) | AU2002319049B2 (enExample) |
| BR (2) | BRPI0211200B8 (enExample) |
| CA (2) | CA2453967C (enExample) |
| CY (1) | CY1108009T1 (enExample) |
| DE (2) | DE60217507T2 (enExample) |
| DK (1) | DK1417228T3 (enExample) |
| EA (1) | EA006603B1 (enExample) |
| ES (2) | ES2281529T3 (enExample) |
| IL (2) | IL159903A0 (enExample) |
| MX (1) | MXPA04000561A (enExample) |
| NO (1) | NO333999B1 (enExample) |
| NZ (2) | NZ531114A (enExample) |
| PL (1) | PL207588B1 (enExample) |
| PT (1) | PT1417228E (enExample) |
| WO (2) | WO2003008443A2 (enExample) |
| ZA (1) | ZA200401320B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050245451A1 (en) * | 2000-04-05 | 2005-11-03 | Pincus Matthew R | Peptides selectively lethal to malignant and transformed mammalian cells |
| BR0207638A (pt) * | 2001-03-08 | 2004-07-27 | Nymox Pharmaceuticals Corp | Métodos de uso de proteìna de filamento neural para tratar tumores e outras condições que requerem a remoção ou destruição de células |
| US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
| JP4587667B2 (ja) * | 2001-07-19 | 2010-11-24 | ナイモックス コーポレーション | 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド |
| US7317077B2 (en) * | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| ATE445714T1 (de) * | 2001-12-04 | 2009-10-15 | Millennium Pharm Inc | 15603, ein mitglied der humanen ionenkanal- familie |
| WO2005014635A2 (en) * | 2003-07-15 | 2005-02-17 | Genova Ltd. | Secreted polypeptide species reduced in cardiovascular disorders |
| BRPI0412664A (pt) * | 2003-07-15 | 2006-09-26 | Ca Nat Research Council | método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth) |
| WO2005075647A1 (en) * | 2004-02-06 | 2005-08-18 | Nymox Corporation | Humanized antibody |
| US20060173490A1 (en) | 2005-02-01 | 2006-08-03 | Boston Scientific Scimed, Inc. | Filter system and method |
| PL1994152T3 (pl) | 2006-02-28 | 2013-05-31 | Nymox Corp | Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek |
| MX2008011570A (es) * | 2006-03-10 | 2008-09-23 | Nymox Corp | Metodo para prevenir o reducir el riesgo o incidencia de cancer usando peptidos basados en proteina de hebra neural. |
| US20080027005A1 (en) * | 2006-07-31 | 2008-01-31 | Paul Averback | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| CA2990264C (en) * | 2007-10-25 | 2022-08-09 | Toray Industries, Inc. | Immune response inducer |
| JP5572938B2 (ja) * | 2007-10-25 | 2014-08-20 | 東レ株式会社 | 免疫誘導剤 |
| US9539327B2 (en) * | 2007-11-26 | 2017-01-10 | The Research Foundation For The State University Of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
| EP2293809B1 (en) * | 2008-04-24 | 2019-05-15 | Therimunex Pharmaceuticals, Inc. | Peptidyl diacylglycerides |
| US8637642B2 (en) | 2010-09-29 | 2014-01-28 | Seattle Genetics, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
| CA2928526A1 (en) | 2013-11-01 | 2015-05-07 | Spherium Biomed S.L. | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
| US20160215031A1 (en) * | 2015-01-27 | 2016-07-28 | Nymox Pharnaceutical Corporation | Method of treating disorders requiring destruction or removal of cells |
| US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| US11628202B2 (en) * | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10183058B2 (en) * | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| US10172910B2 (en) * | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| US10835538B2 (en) | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
| WO2019195851A1 (en) | 2018-04-06 | 2019-10-10 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
| US20200061150A1 (en) | 2018-08-23 | 2020-02-27 | Nymox Corporation | Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function |
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| US20200360466A1 (en) | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
| US11278588B2 (en) | 2019-05-13 | 2022-03-22 | Nymox Corporation | Method of treating lower urinary tract symptoms with fexapotide triflutate |
| US11298400B2 (en) | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US11331374B2 (en) | 2019-07-31 | 2022-05-17 | Nymox Corporation | Focal treatment of prostate cancer |
| US11231421B2 (en) | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68927459T2 (de) * | 1988-12-21 | 1997-04-24 | Gen Hospital Corp | Nachweis einer neurologischen Krankheit oder einer Funktionsstörung |
| US5948634A (en) * | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| KR20000075748A (ko) | 1997-02-26 | 2000-12-26 | 마빈 씨. 구트리 | 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계 |
| JP2002519311A (ja) * | 1998-06-26 | 2002-07-02 | ジョージタウン・ユニバーシティ・メディカル・センター | 細胞死を誘発するための組成物と方法 |
| US7125957B1 (en) * | 1998-09-30 | 2006-10-24 | Riken | VPR mutant protein and its encoding gene having apoptosis-inducing action |
| WO2000034477A2 (en) | 1998-12-11 | 2000-06-15 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| ES2202039T3 (es) * | 1999-01-11 | 2004-04-01 | Leadd B.V. | Uso de agentes inductores de apoptosis en la preparacion de mrdicamentto para el tratamiento de enfermedades autoinmunitarias. |
| WO2000058339A2 (en) | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | 50 human secreted proteins |
| JP2002542766A (ja) | 1999-03-12 | 2002-12-17 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ５０個のヒト分泌タンパク質 |
| AU3628600A (en) | 1999-03-19 | 2000-10-09 | Human Genome Sciences, Inc. | 46 human secreted proteins |
| CA2368927A1 (en) | 1999-03-26 | 2000-10-05 | Craig A. Rosen | 45 human secreted proteins |
| JP2002541833A (ja) | 1999-03-26 | 2002-12-10 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４９個のヒト分泌タンパク質 |
| CN1300779A (zh) | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸 |
| CN1300783A (zh) | 1999-12-23 | 2001-06-27 | 上海生元基因开发有限公司 | 新的人神经元线蛋白及其编码序列 |
| EP1307488A2 (en) * | 2000-06-26 | 2003-05-07 | Millennium Pharmaceuticals, Inc. | A human calcium channel protein and uses thereof |
| US6783969B1 (en) * | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
| WO2002097030A2 (en) | 2001-05-25 | 2002-12-05 | Nymox Corporation | Peptides derived from neural thread proteins and their medical use |
| JP4587667B2 (ja) * | 2001-07-19 | 2010-11-24 | ナイモックス コーポレーション | 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド |
-
2002
- 2002-07-19 JP JP2003514002A patent/JP4587667B2/ja not_active Expired - Lifetime
- 2002-07-19 JP JP2003514001A patent/JP2005507647A/ja active Pending
- 2002-07-19 NZ NZ531114A patent/NZ531114A/en not_active IP Right Cessation
- 2002-07-19 EP EP02748516A patent/EP1417227B1/en not_active Expired - Lifetime
- 2002-07-19 CN CNB028164903A patent/CN100475843C/zh not_active Expired - Fee Related
- 2002-07-19 BR BRPI0211200A patent/BRPI0211200B8/pt not_active IP Right Cessation
- 2002-07-19 KR KR1020047000844A patent/KR100966232B1/ko not_active Expired - Lifetime
- 2002-07-19 NZ NZ531115A patent/NZ531115A/en not_active IP Right Cessation
- 2002-07-19 CA CA2453967A patent/CA2453967C/en not_active Expired - Lifetime
- 2002-07-19 EA EA200400205A patent/EA006603B1/ru unknown
- 2002-07-19 AU AU2002319049A patent/AU2002319049B2/en not_active Ceased
- 2002-07-19 AT AT02748517T patent/ATE353914T1/de active
- 2002-07-19 BR BR0211199-3A patent/BR0211199A/pt not_active IP Right Cessation
- 2002-07-19 DK DK02748517T patent/DK1417228T3/da active
- 2002-07-19 PL PL368912A patent/PL207588B1/pl unknown
- 2002-07-19 ES ES02748517T patent/ES2281529T3/es not_active Expired - Lifetime
- 2002-07-19 US US10/198,070 patent/US7241738B2/en not_active Expired - Lifetime
- 2002-07-19 US US10/198,069 patent/US7192929B2/en not_active Expired - Fee Related
- 2002-07-19 WO PCT/CA2002/001105 patent/WO2003008443A2/en not_active Ceased
- 2002-07-19 PT PT02748517T patent/PT1417228E/pt unknown
- 2002-07-19 ES ES02748516T patent/ES2281528T3/es not_active Expired - Lifetime
- 2002-07-19 IL IL15990302A patent/IL159903A0/xx unknown
- 2002-07-19 AU AU2002319050A patent/AU2002319050B2/en not_active Expired
- 2002-07-19 MX MXPA04000561A patent/MXPA04000561A/es active IP Right Grant
- 2002-07-19 DE DE60217507T patent/DE60217507T2/de not_active Expired - Lifetime
- 2002-07-19 EP EP02748517A patent/EP1417228B1/en not_active Expired - Lifetime
- 2002-07-19 DE DE60218179T patent/DE60218179T2/de not_active Expired - Lifetime
- 2002-07-19 CA CA2453965A patent/CA2453965C/en not_active Expired - Fee Related
- 2002-07-19 WO PCT/CA2002/001106 patent/WO2003008444A2/en not_active Ceased
- 2002-07-19 KR KR1020047000843A patent/KR101005130B1/ko not_active Expired - Fee Related
-
2004
- 2004-01-15 IL IL159903A patent/IL159903A/en active IP Right Grant
- 2004-01-16 NO NO20040222A patent/NO333999B1/no not_active IP Right Cessation
- 2004-02-18 ZA ZA2004/01320A patent/ZA200401320B/en unknown
-
2007
- 2007-04-26 CY CY20071100553T patent/CY1108009T1/el unknown
-
2011
- 2011-02-22 JP JP2011035954A patent/JP2011152133A/ja active Pending
-
2013
- 2013-04-04 JP JP2013078281A patent/JP5622885B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507647A5 (enExample) | ||
| JP2005506061A5 (enExample) | ||
| JP2005521383A5 (enExample) | ||
| JP2004534533A5 (enExample) | ||
| ES2255248T3 (es) | Derivados de antigenos asociados a tumor de la familia mage, y secuencias de acidos nucleicos que los codifican, usados para la preparacion de proteinas de fusion y de composiciones para vacunas. | |
| JP2004529908A5 (enExample) | ||
| CN102596217B (zh) | 经修饰的血管活性肠肽 | |
| JP2019196365A5 (enExample) | ||
| EA010435B1 (ru) | Связывающиеся с tall-1 молекулы и их применение | |
| JP2003531632A (ja) | グルカゴンアンタゴニスト | |
| TW200520772A (en) | Muteins of fibroblast growth factor 21 | |
| JPWO2019140283A5 (ja) | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2004528266A (ja) | 薬物送達用組成物 | |
| CN111690071A (zh) | 一种具有靶向穿膜性的抗肿瘤多肽 | |
| CA2378925A1 (en) | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing | |
| TW201302214A (zh) | 治療或預防皮膚癌之類鋅手指胜肽、其表現質體、及包含其之醫藥組成物 | |
| RU2013113639A (ru) | Иммунотерапевтический способ лечения рака простаты | |
| JPWO2019180000A5 (enExample) | ||
| CN105985447A (zh) | 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
| CN100535005C (zh) | 长链人胰岛素样生长因子(lr3igf-1)及其制备和应用方法 | |
| JP2002523100A (ja) | 新規なヒトリゾチーム遺伝子、それによりコードされたポリペプチド、およびそれらの作製方法 | |
| JP2006501166A5 (enExample) | ||
| RU2614665C1 (ru) | Способ стимуляции репаративного ангиогенеза и регенерации соединительной ткани, при её повреждении, методом генной терапии с использованием видоспецифичных генов белковых факторов vegf и fgf2, в ветеринарии, и генетическая конструкция для реализации заявленного способа | |
| US11459364B2 (en) | Calbindin and BH3 domain chimeric proteins and methods for use | |
| US11299724B2 (en) | Fusion protein, polynucleotide, genetic construct, producer, preparation for regeneration of cartilage |